NCT04977167 2024-10-10
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
HitGen Inc.
Phase 1 Unknown
Clinical Trials
275 trialsNCT05606380 2024-04-16
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05865678 2024-02-21
SKETCh
The Christie NHS Foundation Trust
Unknown
NCT06148220 2024-02-16
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
Huashan Hospital
Phase NA Unknown
NCT05358379 2024-02-07
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT03789097 2024-01-30
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT06202885 2024-01-12
CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy
Seoul St. Mary's Hospital
Unknown
NCT05078840 2024-01-09
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
Grupo Argentino de Tratamiento de la Leucemia Aguda
Unknown
NCT05460767 2023-12-29
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT04407741 2023-12-12
Phase â… /â…¡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05115292 2023-11-09
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
BJ Bioscience, Inc.
Phase 1 Unknown
NCT06120829 2023-11-07
COLD SNAP
San Antonio Uniformed Services Health Education Consortium
Phase NA Unknown
NCT06116734 2023-11-03
Lapelga vs Gastrofil
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Unknown
NCT06106776 2023-10-30
CARdio-Tox
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unknown
NCT04187118 2023-09-21
QUALIPSO-L
University Hospital, Toulouse
Unknown
NCT04985214 2023-09-21
EVEREST
University Hospital, Toulouse
Unknown
NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT06026995 2023-09-07
Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells
Chongqing University Cancer Hospital
Phase 4 Unknown
NCT05296772 2023-09-06
Phase 1 First-in-human Study of JS014
Anwita Biosciences
Phase 1 Unknown
NCT06015464 2023-08-29
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT05390528 2023-08-08
HLX301
Shanghai Henlius Biotech
Phase 1/2 Unknown
NCT05967975 2023-08-01
Elastography and Treatment of Lymphoma
Assiut University
Unknown
NCT02825836 2023-07-13
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Telios Pharma, Inc.
Phase 1/2 Unknown
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05576532 2023-06-28
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05907447 2023-06-18
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Ruijin Hospital
Unknown
NCT05892146 2023-06-07
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
National Cheng-Kung University Hospital
Phase NA Unknown
NCT05863845 2023-05-18
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
Ruijin Hospital
Phase NA Unknown
NCT05852028 2023-05-10
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
Ruijin Hospital
Unknown
NCT05834751 2023-04-28
the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
The First Hospital of Jilin University
Phase NA Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT03510767 2023-04-14
A Study of TQ-B3525 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05510544 2023-03-13
Plerixafor for Poorly Mobilized Lymphoma
Peking University
Phase 4 Unknown
NCT05004961 2023-03-03
The Performance of Multi-tracer Multimodality PET in Lymphoma
Peking University Cancer Hospital & Institute
Unknown
NCT05390632 2023-03-03
Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas
Peking University Cancer Hospital & Institute
Unknown
NCT03573362 2023-02-17
Effect of Needle Size in Diagnostic Yield of EBUS-TBNA in Sarcoidosis and Lymphoma
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Unknown
NCT05400876 2023-02-14
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT05680038 2023-01-11
Penpulimab in Maintenance Therapy in Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT05672420 2023-01-05
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT03775525 2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1 Unknown
NCT05654038 2022-12-21
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05651100 2022-12-14
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Kecellitics Biotech Company Ltd
Phase 1/2 Unknown
NCT05565898 2022-11-01
PET/CT Vs Bone Marrow Biopsy in Exclusion of Bone Marrow Infiltration for Initial Staging of Lymphoma
Assiut University
Unknown
NCT05600959 2022-11-01
Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
Beijing Friendship Hospital
Unknown
NCT05227898 2022-10-25
RESTORE
Blue Note Therapeutics
Phase NA Unknown
NCT04352556 2022-09-23
COVID19-hematological Malignancies: the Italian Hematology Alliance
Ospedale di Circolo - Fondazione Macchi
Unknown
NCT02678299 2022-08-04
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
University of Aarhus
Phase 1/2 Unknown
NCT03985696 2022-07-25
ExoReBLy
University Hospital, Limoges
Phase NA Unknown
NCT05454878 2022-07-12
Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy
Chinese PLA General Hospital
Unknown